SGC releases TEPs to support research into new drug discovery targets

June 16th, 2017- SGC’s Target Enabling Package (TEP) Evaluation Group has approved five new TEPs for protein targets related to cancer, metabolic diseases and neuropsychiatric disorders.

TEPs enable scientists to research understudied proteins that have been genetically linked to human disease. The SGC generates and disseminates structural data, assays and other key research information and tools on these proteins to the scientific community.

The five TEPs recently released focus on the following genes:

  • DCLRE1A: A DNA exonuclease involved in the repair of DNA damage, with the unique capability to digest through cross-linked nucleotides. Knocking down DCLRE1A expression sensitizes cells to chemotherapeutic agents such as cisplatins and mitomycin C.
  • AASS: A bi-functional enzyme in lysine catabolism that sits upstream of ALDH7A1, the molecular cause of pyridoxine-dependent epilepsy.
  • WNK3: A protein kinase linked to hypertension. Its inhibition has been shown to reduce cerebral injury after ischemic stroke.
  • DPAGT1: An integral membrane enzyme involved in protein N-glycosylation. Mutations in DPAGT1 cause congenital disorder of glycosylation type Ij and congenital myasthenic syndrome with tubular aggregates.
  • LIMK1: A protein kinase that is a therapeutic target downstream of the fragile X mental retardation 1 gene product FMRP.

The TEPs program, which is funded by the Wellcome Trust, will generate 24 TEPs by June 2020.

For more information on the TEPs program or to nominate a protein to be the subject of a TEP, please see:

glqxz9283 sfy39587stf02 mnesdcuix8